35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Inflammation, Oral Pain and Pharyngeal Discomfort (HA35-CHEW)
Prospective Single-Arm Open-Label Clinical Study of 35-kDa Hyaluronan Fragment (HA35) Chewable Tablets for Gingival Pain, Periodontal Inflammation, Gingival Recession and Pharyngeal Itch-Pain
To explore efficacy and safety of 35-kDa hyaluronan fragment (HA35) chewable tablets for relief of tooth-gingival pain, periodontal gingival inflammation, mild gingival recession, and pharyngeal itching-pain. Participants chew six tablets per dose, three times daily for 28 consecutive days. Assess subjective oral-pharyngeal symptoms, gingival inflammation, estimated gingival regrowth and safety events.
研究概览
地位
详细说明
This is prospective, single-arm, open-label pilot clinical study. Eligible adult participants with periodontal condition, mild gingival recession and oral-gingival pain or pharyngeal discomfort receive HA35 chewable tablets. Each tablet weighs 600 mg containing 300 mg 35-kDa hyaluronan fragment. Subjects chew six tablets each administration (3 tablets on each molar side), three times daily for total 18 tablets/day (5.4 g HA35/day), for 28 consecutive days. Tablets dissolve by saliva in oral cavity after chewing. Evaluations are performed at baseline; 3 minutes post-first dose; 30 minutes post-first dose; Day 1, Day 7, Day 21, Day 28. Investigator assess gingival redness/swelling, exposed root length for estimated gingival regrowth. Subject self-report pain, itch-pain of throat. Exploratory facial-tissue related assessments are performed at Day 28. Adverse events are monitored throughout whole 28-day study period. Target enrollment: 30 adult participants.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Mizhou Hui
- 电话号码:13484005199
- 邮箱:mizhou.hui@alumni.utoronto.ca
学习地点
-
-
Shandong
-
Qingdao、Shandong、中国
- Nakhia Impex LLC
-
接触:
- Xiaoxiao Jia
- 电话号码:15621486915
- 邮箱:15621486915@163.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18-75 years old, male or female adult.
- Clinical findings of periodontal disease with mild gingival recession; with at least one of following: chronic gingival/tooth-root pain; pain after dental procedure (restoration, scaling, extraction, transplantation etc.); subjective pharyngeal itching or pharyngeal pain.
- Able to independently complete NRS scale self-assessment.
- Able to follow full 28-days three-times-daily chewable-tablet protocol.
- Voluntarily sign written informed-consent document.
Exclusion Criteria:
- Severe periodontal disease requiring immediate surgical intervention; active oral ulcer, oral malignant lesion.
- Pregnant or lactating women.
- Known hypersensitivity / allergy to hyaluronan / sodium hyaluronate or tablet excipients.
- Severe gastrointestinal diseases.
- Simultaneous participation in other oral-pharyngeal-related clinical trials.
- Psychiatric disorders that compromise study compliance.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:HA35 Chewable Tablets
|
Intervention description: Each tablet 600 mg containing 300 mg HA35. Chew six tablets per dose (3 each side molars), three times daily, total 18 tablets/day (5.4 g HA35/day), 28 consecutive days. Tablets dissolve in saliva after chewing. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Primary Outcome Measures
大体时间:Baseline, 3 minutes after first administration, Day-1, Day-7, Day-28
|
Participant-reported 0-10 numerical rating scale for tooth and gingival pain; 0=no pain,10=worst imaginable pain |
Baseline, 3 minutes after first administration, Day-1, Day-7, Day-28
|
|
Pharyngeal Itching-Pain NRS Score
大体时间:Baseline,30 minutes after first administration, Day-1, Day-7, Day-28
|
Participant-reported 0-10 NRS for throat itching and pain;0=no symptom, 10=worst imaginable itch-pain |
Baseline,30 minutes after first administration, Day-1, Day-7, Day-28
|
|
Gingival Inflammatory Redness-Swelling NRS Score
大体时间:Baseline, Day-1, Day-7, Day-21, Day-28
|
Investigator-rated composite 0-10 score of gingival redness and swelling;0=no inflammation;10=severe gingival redness and swelling |
Baseline, Day-1, Day-7, Day-21, Day-28
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Estimated Gingival Regrowth Length (mm)
大体时间:Baseline, Day-21, Day-28
|
Investigator measurement of exposed tooth-root length using 1-mm precision ruler; calculate estimated gingival regrowth from baseline |
Baseline, Day-21, Day-28
|
|
Exploratory Facial-tissue Reduction Score
大体时间:Baseline, Day-28
|
Investigator visual-tactile 0-10 rating scale (exploratory only): reduction of facial roundness, forehead-skin thickness, eyelid thickness, double-chin prominence;0=no reduction;10=maximum reduction. Exploratory endpoint only |
Baseline, Day-28
|
|
Participant Overall Satisfaction Score
大体时间:Day-28 end-of-treatment
|
Participant self-reported overall satisfaction 0-10 scale for oral-pharyngeal improvement. 0=most dissatisfied, 10=most satisfied |
Day-28 end-of-treatment
|
|
Adverse Event Incidence
大体时间:Entire 28-day study period
|
Incidence of product-related adverse events including oral mucosal irritation, hypersensitivity, gastrointestinal discomfort, throat irritation |
Entire 28-day study period
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- HA35202612
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.